Home The Word Brain	My Amedeo FAQ Privacy About
	2049 Chinese The 20K Word Road to Mandarin Proficiency By B. S. Kamps et al.

Prostate Cancer

Free Subscription Articles published in Oncogene Retrieve available abstracts of 97 articles: HTML format

Single Articles

June 2024
1. LIN G, Zhang F, Weng X, Hong Z, et al
   Role of gut microbiota in the pathogenesis of castration-resistant prostate cancer: a comprehensive study using sequencing and animal models.
   Oncogene. 2024 Jun 17. doi: 10.1038/s41388-024-03073.
   PubMed     Abstract available
   
   
   
2. CHEN B, Xu P, Yang JC, Nip C, et al
   Plexin D1 emerges as a novel target in the development of neural lineage plasticity in treatment-resistant prostate cancer.
   Oncogene. 2024 Jun 14. doi: 10.1038/s41388-024-03081.
   PubMed     Abstract available
   
   
   
3. FRANCIS JC, Capper A, Rust AG, Ferro K, et al
   Identification of genes that promote PI3K pathway activation and prostate tumour formation.
   Oncogene. 2024;43:1824-1835.
   PubMed     Abstract available
   
   
   May 2024
4. ZHAO J, Shen J, Mao L, Yang T, et al
   Cancer associated fibroblast secreted miR-432-5p targets CHAC1 to inhibit ferroptosis and promote acquired chemoresistance in prostate cancer.
   Oncogene. 2024 May 20. doi: 10.1038/s41388-024-03057.
   PubMed     Abstract available
   
   
   
5. TAHSIN S, Sane NS, Cernyar B, Jiang L, et al
   AR loss in prostate cancer stroma mediated by NF-kappaB and p38-MAPK signaling disrupts stromal morphogen production.
   Oncogene. 2024 May 20. doi: 10.1038/s41388-024-03064.
   PubMed     Abstract available
   
   
   
6. BEIER AK, Ebersbach C, Siciliano T, Scholze J, et al
   Targeting the glutamine metabolism to suppress cell proliferation in mesenchymal docetaxel-resistant prostate cancer.
   Oncogene. 2024 May 15. doi: 10.1038/s41388-024-03059.
   PubMed     Abstract available
   
   
   April 2024
7. RAWAT C, Heemers HV
   Alternative splicing in prostate cancer progression and therapeutic resistance.
   Oncogene. 2024 Apr 24. doi: 10.1038/s41388-024-03036.
   PubMed     Abstract available
   
   
   
8. ARRIAGA JM, Ronaldson-Bouchard K, Picech F, Nunes de Almeida F, et al
   Correction: In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasis.
   Oncogene. 2024 Apr 16. doi: 10.1038/s41388-024-03031.
   PubMed    
   
   
   
9. LI Y, Lv L, Ye M, Xie N, et al
   PDIA2 has a dual function in promoting androgen deprivation therapy induced venous thrombosis events and castrate resistant prostate cancer progression.
   Oncogene. 2024 Apr 8. doi: 10.1038/s41388-024-03024.
   PubMed     Abstract available
   
   
   
10. CHEN M, Zou C, Tian Y, Li W, et al
    An integrated ceRNA network identifies miR-375 as an upregulated miRNA playing a tumor suppressive role in aggressive prostate cancer.
    Oncogene. 2024 Apr 2. doi: 10.1038/s41388-024-03011.
    PubMed     Abstract available
    
    
    March 2024
11. YI Q, Han X, Yu HG, Chen HY, et al
    SC912 inhibits AR-V7 activity in castration-resistant prostate cancer by targeting the androgen receptor N-terminal domain.
    Oncogene. 2024 Mar 26. doi: 10.1038/s41388-024-02944.
    PubMed     Abstract available
    
    
    
12. GUO S, Miao M, Wu Y, Pan D, et al
    DHODH inhibition represents a therapeutic strategy and improves abiraterone treatment in castration-resistant prostate cancer.
    Oncogene. 2024 Mar 13. doi: 10.1038/s41388-024-03005.
    PubMed     Abstract available
    
    
    
13. ARRIAGA JM, Ronaldson-Bouchard K, Picech F, Nunes de Almeida F, et al
    In vivo genome-wide CRISPR screening identifies CITED2 as a driver of prostate cancer bone metastasis.
    Oncogene. 2024 Mar 7. doi: 10.1038/s41388-024-02995.
    PubMed     Abstract available
    
    
    
14. LI J, Hong Z, Zhang J, Zheng S, et al
    Lysine methyltransferase SMYD2 enhances androgen receptor signaling to modulate CRPC cell resistance to enzalutamide.
    Oncogene. 2024;43:744-757.
    PubMed     Abstract available
    
    
    January 2024
15. CHAO Y, Chen Y, Zheng W, Demanelis K, et al
    Synthetic lethal combination of CHK1 and WEE1 inhibition for treatment of castration-resistant prostate cancer.
    Oncogene. 2024 Jan 25. doi: 10.1038/s41388-024-02939.
    PubMed     Abstract available
    
    
    
16. RODRIGUEZ TIRADO C, Wang C, Li X, Deng S, et al
    UBE2J1 is the E2 ubiquitin-conjugating enzyme regulating androgen receptor degradation and antiandrogen resistance.
    Oncogene. 2024;43:265-280.
    PubMed     Abstract available
    
    
    December 2023
17. FERRARI MG, Jimenez-Uribe AP, Wang L, Hoeppner LH, et al
    Myeloid differentiation factor-2/LY96, a potential predictive biomarker of metastasis and poor outcomes in prostate cancer: clinical implications as a potential therapeutic target.
    Oncogene. 2023 Dec 23. doi: 10.1038/s41388-023-02925.
    PubMed     Abstract available
    
    
    
18. MILLER KA, Degan S, Wang Y, Cohen J, et al
    Correction: PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression.
    Oncogene. 2023 Dec 14. doi: 10.1038/s41388-023-02920.
    PubMed    
    
    
    
19. CHAUHAN SS, Casillas AL, Vizzerra AD, Liou H, et al
    PIM1 drives lipid droplet accumulation to promote proliferation and survival in prostate cancer.
    Oncogene. 2023 Dec 14. doi: 10.1038/s41388-023-02914.
    PubMed     Abstract available
    
    
    November 2023
20. EIGENTLER A, Handle F, Schanung S, Degen A, et al
    Glucocorticoid treatment influences prostate cancer cell growth and the tumor microenvironment via altered glucocorticoid receptor signaling in prostate fibroblasts.
    Oncogene. 2023 Nov 29. doi: 10.1038/s41388-023-02901.
    PubMed     Abstract available
    
    
    
21. CUI H, Wang Y, Zhou T, Qu L, et al
    Targeting DGAT1 inhibits prostate cancer cells growth by inducing autophagy flux blockage via oxidative stress.
    Oncogene. 2023 Nov 16. doi: 10.1038/s41388-023-02878.
    PubMed     Abstract available
    
    
    October 2023
22. MILLER KA, Degan S, Wang Y, Cohen J, et al
    PTEN-regulated PI3K-p110 and AKT isoform plasticity controls metastatic prostate cancer progression.
    Oncogene. 2023 Oct 24. doi: 10.1038/s41388-023-02875.
    PubMed     Abstract available
    
    
    September 2023
23. ADVANI R, Luzzi S, Scott E, Dalgliesh C, et al
    Epithelial specific splicing regulator proteins as emerging oncogenes in aggressive prostate cancer.
    Oncogene. 2023 Sep 26. doi: 10.1038/s41388-023-02838.
    PubMed     Abstract available
    
    
    August 2023
24. BUNAY J, Kossai M, Damon-Soubeyrant C, De Haze A, et al
    Persistent organic pollutants promote aggressiveness in prostate cancer.
    Oncogene. 2023 Aug 17. doi: 10.1038/s41388-023-02788.
    PubMed     Abstract available
    
    
    
25. WU T, Zhang Y, Han Q, Lu X, et al
    Klotho-beta attenuates Rab8a-mediated exosome regulation and promotes prostate cancer progression.
    Oncogene. 2023 Aug 15. doi: 10.1038/s41388-023-02807.
    PubMed     Abstract available
    
    
    July 2023
26. BUSKIN A, Scott E, Nelson R, Gaughan L, et al
    Engineering prostate cancer in vitro: what does it take?
    Oncogene. 2023 Jul 12. doi: 10.1038/s41388-023-02776.
    PubMed     Abstract available
    
    
    
27. ZHOU Z, Jia D, Kwon O, Li S, et al
    Androgen-regulated stromal complement component 7 (C7) suppresses prostate cancer growth.
    Oncogene. 2023 Jul 3. doi: 10.1038/s41388-023-02759.
    PubMed     Abstract available
    
    
    June 2023
28. VLAJIC K, Pennington Kluger H, Bie W, Merrill BJ, et al
    Appearance of tuft cells during prostate cancer progression.
    Oncogene. 2023 Jun 29. doi: 10.1038/s41388-023-02743.
    PubMed     Abstract available
    
    
    
29. BLATT EB, Parra K, Neeb A, Buroni L, et al
    Critical role of antioxidant programs in enzalutamide-resistant prostate cancer.
    Oncogene. 2023 Jun 24. doi: 10.1038/s41388-023-02756.
    PubMed     Abstract available
    
    
    May 2023
30. LIN Z, Agarwal S, Tan S, Shi H, et al
    Palmitoyl acyltransferase ZDHHC7 inhibits androgen receptor and suppresses prostate cancer.
    Oncogene. 2023 May 17. doi: 10.1038/s41388-023-02718.
    PubMed     Abstract available
    
    
    April 2023
31. LI Z, Jiao X, Robertson AG, Di Sante G, et al
    The DACH1 gene is frequently deleted in prostate cancer, restrains prostatic intraepithelial neoplasia, decreases DNA damage repair, and predicts therapy responses.
    Oncogene. 2023 Apr 24. doi: 10.1038/s41388-023-02668.
    PubMed     Abstract available
    
    
    
32. KIM H, Barua A, Huang L, Zhou T, et al
    The cancer testis antigen TDRD1 regulates prostate cancer proliferation by associating with the snRNP biogenesis machinery.
    Oncogene. 2023 Apr 12. doi: 10.1038/s41388-023-02690.
    PubMed     Abstract available
    
    
    
33. CAMERON S, Deblois G, Hawley JR, Qamra A, et al
    Chronic hypoxia favours adoption to a castration-resistant cell state in prostate cancer.
    Oncogene. 2023 Apr 5. doi: 10.1038/s41388-023-02680.
    PubMed     Abstract available
    
    
    March 2023
34. YENDE AS, Williams EC, Pletcher A, Helfand A, et al
    TRIM28 promotes luminal cell plasticity in a mouse model of prostate cancer.
    Oncogene. 2023 Mar 8. doi: 10.1038/s41388-023-02655.
    PubMed     Abstract available
    
    
    
35. NIKESITCH N, Beraldi E, Zhang F, Adomat H, et al
    Chaperone-mediated autophagy promotes PCa survival during ARPI through selective proteome remodeling.
    Oncogene. 2023;42:748-758.
    PubMed     Abstract available
    
    
    
36. DING Y, Chen J, Li S, Wren JD, et al
    EWI2 and its relatives in Tetraspanin-enriched membrane domains regulate malignancy.
    Oncogene. 2023;42:861-868.
    PubMed     Abstract available
    
    
    February 2023
37. GRITSINA G, Yu J
    CXCR7 as a novel therapeutic target for advanced prostate cancer.
    Oncogene. 2023 Feb 9. doi: 10.1038/s41388-023-02597.
    PubMed     Abstract available
    
    
    
38. SCOTT E, Hodgson K, Calle B, Turner H, et al
    Upregulation of GALNT7 in prostate cancer modifies O-glycosylation and promotes tumour growth.
    Oncogene. 2023 Feb 1. doi: 10.1038/s41388-023-02604.
    PubMed     Abstract available
    
    
    January 2023
39. YANG JC, Xu P, Ning S, Wasielewski LJ, et al
    Novel inhibition of AKR1C3 and androgen receptor axis by PTUPB synergizes enzalutamide treatment in advanced prostate cancer.
    Oncogene. 2023 Jan 3. doi: 10.1038/s41388-022-02566.
    PubMed     Abstract available
    
    
    December 2022
40. FAN L, Gong Y, He Y, Gao WQ, et al
    TRIM59 is suppressed by androgen receptor and acts to promote lineage plasticity and treatment-induced neuroendocrine differentiation in prostate cancer.
    Oncogene. 2022 Dec 21. doi: 10.1038/s41388-022-02498.
    PubMed     Abstract available
    
    
    October 2022
41. KIKUNO N, Shiina H, Urakami S, Kawamoto K, et al
    Retraction Note: Knockdown of astrocyte-elevated gene-1 inhibits prostate cancer progression through upregulation of FOXO3a activity.
    Oncogene. 2022 Oct 19. pii: 10.1038/s41388-022-02501.
    PubMed    
    
    
    
42. GUO Y, He J, Zhang H, Chen R, et al
    Linear ubiquitination of PTEN impairs its function to promote prostate cancer progression.
    Oncogene. 2022 Oct 3. pii: 10.1038/s41388-022-02485.
    PubMed     Abstract available
    
    
    
43. TAN Q, Liu Z, Gao X, Wang Y, et al
    Celastrol recruits UBE3A to recognize and degrade the DNA binding domain of steroid receptors.
    Oncogene. 2022;41:4754-4767.
    PubMed     Abstract available
    
    
    September 2022
44. AHN S, Saha A, Clark R, Kolonin MG, et al
    CXCR4 and CXCR7 signaling promotes tumor progression and obesity-associated epithelial-mesenchymal transition in prostate cancer cells.
    Oncogene. 2022 Sep 10. pii: 10.1038/s41388-022-02466.
    PubMed     Abstract available
    
    
    
45. WANG C, Li W, Hu Q, Feng N, et al
    Transgenic construction and functional miRNA analysis identify the role of miR-7 in prostate cancer suppression.
    Oncogene. 2022 Sep 10. pii: 10.1038/s41388-022-02461.
    PubMed     Abstract available
    
    
    
46. WANG X, Brea L, Lu X, Gritsina G, et al
    FOXA1 inhibits hypoxia programs through transcriptional repression of HIF1A.
    Oncogene. 2022;41:4259-4270.
    PubMed     Abstract available
    
    
    
47. LI C, Liu J, He D, Mao F, et al
    GSTM2 is a key molecular determinant of resistance to SG-ARIs.
    Oncogene. 2022;41:4498-4511.
    PubMed     Abstract available
    
    
    August 2022
48. WANG J, Li J, Yin L, Pu T, et al
    Neuropilin-2 promotes lineage plasticity and progression to neuroendocrine prostate cancer.
    Oncogene. 2022 Aug 19. pii: 10.1038/s41388-022-02437.
    PubMed     Abstract available
    
    
    
49. MOUILLET-RICHARD S, Martin-Lanneree S, Le Corre D, Hirsch TZ, et al
    A proof of concept for targeting the PrP(C) - Amyloid beta peptide interaction in basal prostate cancer and mesenchymal colon cancer.
    Oncogene. 2022 Aug 12. pii: 10.1038/s41388-022-02430.
    PubMed     Abstract available
    
    
    
50. IPSEN MB, Sorensen EMG, Thomsen EA, Weiss S, et al
    A genome-wide CRISPR-Cas9 knockout screen identifies novel PARP inhibitor resistance genes in prostate cancer.
    Oncogene. 2022 Aug 6. pii: 10.1038/s41388-022-02427.
    PubMed     Abstract available
    
    
    July 2022
51. LI Z, Li B, Yu H, Wang P, et al
    DNMT1-mediated epigenetic silencing of TRAF6 promotes prostate cancer tumorigenesis and metastasis by enhancing EZH2 stability.
    Oncogene. 2022 Jul 8. pii: 10.1038/s41388-022-02404.
    PubMed     Abstract available
    
    
    
52. WENTA T, Schmidt A, Zhang Q, Devarajan R, et al
    Disassembly of alpha6beta4-mediated hemidesmosomal adhesions promotes tumorigenesis in PTEN-negative prostate cancer by targeting plectin to focal adhesions.
    Oncogene. 2022 Jul 1. pii: 10.1038/s41388-022-02389.
    PubMed     Abstract available
    
    
    June 2022
53. DUTTA S, Polavaram NS, Islam R, Bhattacharya S, et al
    Neuropilin-2 regulates androgen-receptor transcriptional activity in advanced prostate cancer.
    Oncogene. 2022 Jun 27. pii: 10.1038/s41388-022-02382.
    PubMed     Abstract available
    
    
    
54. SUN F, Wang X, Hu J, Liu J, et al
    RUVBL1 promotes enzalutamide resistance of prostate tumors through the PLXNA1-CRAF-MAPK pathway.
    Oncogene. 2022;41:3239-3250.
    PubMed     Abstract available
    
    
    May 2022
55. KHANDRIKA L, Lieberman R, Koul S, Kumar B, et al
    Retraction Note: Hypoxia-associated p38 mitogen-activated protein kinase-mediated androgen receptor activation and increased HIF-1alpha levels contribute to emergence of an aggressive phenotype in prostate cancer.
    Oncogene. 2022 May 19. pii: 10.1038/s41388-022-02357.
    PubMed    
    
    
    
56. CONSTANTIN TA, Greenland KK, Varela-Carver A, Bevan CL, et al
    Transcription associated cyclin-dependent kinases as therapeutic targets for prostate cancer.
    Oncogene. 2022 May 14. pii: 10.1038/s41388-022-02347.
    PubMed     Abstract available
    
    
    
57. EHSANI M, Bartsch S, Rasa SMM, Dittmann J, et al
    The natural compound atraric acid suppresses androgen-regulated neo-angiogenesis of castration-resistant prostate cancer through angiopoietin 2.
    Oncogene. 2022 May 5. pii: 10.1038/s41388-022-02333.
    PubMed     Abstract available
    
    
    
58. JI D, Shang G, Wei E, Jia Y, et al
    Targeting CDCP1 gene transcription coactivated by BRD4 and CBP/p300 in castration-resistant prostate cancer.
    Oncogene. 2022 May 5. pii: 10.1038/s41388-022-02327.
    PubMed     Abstract available
    
    
    
59. ZHANG Y, Xu Z, Wen W, Liu Z, et al
    The microRNA-3622 family at the 8p21 locus exerts oncogenic effects by regulating the p53-downstream gene network in prostate cancer progression.
    Oncogene. 2022 May 2. pii: 10.1038/s41388-022-02289.
    PubMed     Abstract available
    
    
    April 2022
60. GAO P, Hao JL, Xie QW, Han GQ, et al
    PELO facilitates PLK1-induced the ubiquitination and degradation of Smad4 and promotes the progression of prostate cancer.
    Oncogene. 2022 Apr 18. pii: 10.1038/s41388-022-02316.
    PubMed     Abstract available
    
    
    
61. LIN HY, Ko CJ, Lo TY, Wu SR, et al
    Matriptase-2/NR4A3 axis switches TGF-beta action toward suppression of prostate cancer cell invasion, tumor growth, and metastasis.
    Oncogene. 2022 Apr 13. pii: 10.1038/s41388-022-02303.
    PubMed     Abstract available
    
    
    
62. COPELLO VA, Burnstein KL
    The kinesin KIF20A promotes progression to castration-resistant prostate cancer through autocrine activation of the androgen receptor.
    Oncogene. 2022 Apr 13. pii: 10.1038/s41388-022-02307.
    PubMed     Abstract available
    
    
    
63. BRAMHECHA YM, Guerard KP, Audet-Walsh E, Rouzbeh S, et al
    Fatty acid oxidation enzyme Delta3, Delta2-enoyl-CoA isomerase 1 (ECI1) drives aggressive tumor phenotype and predicts poor clinical outcome in prostate cancer patients.
    Oncogene. 2022 Apr 11. pii: 10.1038/s41388-022-02276.
    PubMed     Abstract available
    
    
    March 2022
64. WANG C, Leavenworth J, Zhang C, Liu Z, et al
    Epigenetic regulation of EIF4A1 through DNA methylation and an oncogenic role of eIF4A1 through BRD2 signaling in prostate cancer.
    Oncogene. 2022 Mar 31. pii: 10.1038/s41388-022-02272.
    PubMed     Abstract available
    
    
    
65. WANG L, Wang J, Yin X, Guan X, et al
    GIPC2 interacts with Fzd7 to promote prostate cancer metastasis by activating WNT signaling.
    Oncogene. 2022 Mar 28. pii: 10.1038/s41388-022-02255.
    PubMed     Abstract available
    
    
    February 2022
66. DE WET L, Williams A, Gillard M, Kregel S, et al
    Correction to: SOX2 mediates metabolic reprogramming of prostate cancer cells.
    Oncogene. 2022 Feb 10. pii: 10.1038/s41388-022-02228.
    PubMed    
    
    
    January 2022
67. YI Y, Li Y, Li C, Wu L, et al
    Methylation-dependent and -independent roles of EZH2 synergize in CDCA8 activation in prostate cancer.
    Oncogene. 2022 Jan 29. pii: 10.1038/s41388-022-02208.
    PubMed     Abstract available
    
    
    
68. MELNYK JE, Steri V, Nguyen HG, Hwang YC, et al
    Targeting a splicing-mediated drug resistance mechanism in prostate cancer by inhibiting transcriptional regulation by PKCbeta1.
    Oncogene. 2022 Jan 27. pii: 10.1038/s41388-022-02179.
    PubMed     Abstract available
    
    
    
69. DE WET L, Williams A, Gillard M, Kregel S, et al
    SOX2 mediates metabolic reprogramming of prostate cancer cells.
    Oncogene. 2022 Jan 24. pii: 10.1038/s41388-021-02157.
    PubMed     Abstract available
    
    
    
70. XU L, Zhao B, Butler W, Xu H, et al
    Targeting glutamine metabolism network for the treatment of therapy-resistant prostate cancer.
    Oncogene. 2022 Jan 20. pii: 10.1038/s41388-021-02155.
    PubMed     Abstract available
    
    
    
71. CANNISTRACI A, Hascoet P, Ali A, Mundra P, et al
    MiR-378a inhibits glucose metabolism by suppressing GLUT1 in prostate cancer.
    Oncogene. 2022 Jan 17. pii: 10.1038/s41388-022-02178.
    PubMed     Abstract available
    
    
    
72. HAN W, Liu M, Han D, Li M, et al
    RB1 loss in castration-resistant prostate cancer confers vulnerability to LSD1 inhibition.
    Oncogene. 2022 Jan 3. pii: 10.1038/s41388-021-02135.
    PubMed     Abstract available
    
    
    
73. MCCANN JJ, Vasilevskaya IA, McNair C, Gallagher P, et al
    Mutant p53 elicits context-dependent pro-tumorigenic phenotypes.
    Oncogene. 2022;41:444-458.
    PubMed     Abstract available
    
    
    
74. ZHANG B, Zhang M, Yang Y, Li Q, et al
    Targeting KDM4A-AS1 represses AR/AR-Vs deubiquitination and enhances enzalutamide response in CRPC.
    Oncogene. 2022;41:387-399.
    PubMed     Abstract available
    
    
    December 2021
75. MIRZAKHANI K, Kallenbach J, Rasa SMM, Ribaudo F, et al
    Correction to: The androgen receptor-lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells.
    Oncogene. 2021 Dec 20. pii: 10.1038/s41388-021-02125.
    PubMed    
    
    
    November 2021
76. LEE YC, Lin SC, Yu G, Zhu M, et al
    Prostate tumor-induced stromal reprogramming generates Tenascin C that promotes prostate cancer metastasis through YAP/TAZ inhibition.
    Oncogene. 2021 Nov 29. pii: 10.1038/s41388-021-02131.
    PubMed     Abstract available
    
    
    
77. MAZZU YZ, Liao YR, Nandakumar S, Jehane LE, et al
    Prognostic and therapeutic significance of COP9 signalosome subunit CSN5 in prostate cancer.
    Oncogene. 2021 Nov 20. pii: 10.1038/s41388-021-02118.
    PubMed     Abstract available
    
    
    October 2021
78. CHERIF C, Nguyen DT, Paris C, Le TK, et al
    Menin inhibition suppresses castration-resistant prostate cancer and enhances chemosensitivity.
    Oncogene. 2021 Oct 28. pii: 10.1038/s41388-021-02039.
    PubMed     Abstract available
    
    
    
79. MIRZAKHANI K, Kallenbach J, Rasa SMM, Ribaudo F, et al
    The androgen receptor-lncRNASAT1-AKT-p15 axis mediates androgen-induced cellular senescence in prostate cancer cells.
    Oncogene. 2021 Oct 19. pii: 10.1038/s41388-021-02060.
    PubMed     Abstract available
    
    
    
80. HU L, Chen X, Narwade N, Lim MGL, et al
    Single-cell analysis reveals androgen receptor regulates the ER-to-Golgi trafficking pathway with CREB3L2 to drive prostate cancer progression.
    Oncogene. 2021 Oct 5. pii: 10.1038/s41388-021-02026.
    PubMed     Abstract available
    
    
    September 2021
81. LABANCA E, Bizzotto J, Sanchis P, Anselmino N, et al
    Prostate cancer castrate resistant progression usage of non-canonical androgen receptor signaling and ketone body fuel.
    Oncogene. 2021 Sep 28. pii: 10.1038/s41388-021-02008.
    PubMed     Abstract available
    
    
    
82. ZHU M, Peng R, Liang X, Lan Z, et al
    P4HA2-induced prolyl hydroxylation suppresses YAP1-mediated prostate cancer cell migration, invasion, and metastasis.
    Oncogene. 2021 Sep 1. pii: 10.1038/s41388-021-02000.
    PubMed     Abstract available
    
    
    August 2021
83. PARK SH, Fong KW, Mong E, Martin MC, et al
    Going beyond Polycomb: EZH2 functions in prostate cancer.
    Oncogene. 2021 Aug 4. pii: 10.1038/s41388-021-01982.
    PubMed     Abstract available
    
    
    July 2021
84. LIU C, Armstrong CM, Ning S, Yang JC, et al
    ARVib suppresses growth of advanced prostate cancer via inhibition of androgen receptor signaling.
    Oncogene. 2021 Jul 16. pii: 10.1038/s41388-021-01914.
    PubMed     Abstract available
    
    
    June 2021
85. HAGIWARA M, Fushimi A, Yamashita N, Bhattacharya A, et al
    MUC1-C activates the PBAF chromatin remodeling complex in integrating redox balance with progression of human prostate cancer stem cells.
    Oncogene. 2021 Jun 23. pii: 10.1038/s41388-021-01899.
    PubMed     Abstract available
    
    
    
86. LAUNONEN KM, Paakinaho V, Sigismondo G, Malinen M, et al
    Chromatin-directed proteomics-identified network of endogenous androgen receptor in prostate cancer cells.
    Oncogene. 2021 Jun 14. pii: 10.1038/s41388-021-01887.
    PubMed     Abstract available
    
    
    
87. PAN T, Lin SC, Lee YC, Yu G, et al
    Statins reduce castration-induced bone marrow adiposity and prostate cancer progression in bone.
    Oncogene. 2021 Jun 14. pii: 10.1038/s41388-021-01874.
    PubMed     Abstract available
    
    
    
88. LIAO Y, Liu Y, Shao Z, Xia X, et al
    A new role of GRP75-USP1-SIX1 protein complex in driving prostate cancer progression and castration resistance.
    Oncogene. 2021 Jun 2. pii: 10.1038/s41388-021-01851.
    PubMed     Abstract available
    
    
    May 2021
89. LEE HC, Ou CH, Huang YC, Hou PC, et al
    Correction: YAP1 overexpression contributes to the development of enzalutamide resistance by induction of cancer stemness and lipid metabolism in prostate cancer.
    Oncogene. 2021 May 19. pii: 10.1038/s41388-021-01836.
    PubMed    
    
    
    
90. CRONIN R, Brooke GN, Prischi F
    The role of the p90 ribosomal S6 kinase family in prostate cancer progression and therapy resistance.
    Oncogene. 2021 May 10. pii: 10.1038/s41388-021-01810.
    PubMed     Abstract available
    
    
    
91. ZHU Y, Dalrymple SL, Coleman I, Zheng SL, et al
    Correction: Role of androgen receptor splice variant-7 (AR-V7) in prostate cancer resistance to 2nd-generation androgen receptor signaling inhibitors.
    Oncogene. 2021 May 6. pii: 10.1038/s41388-021-01805.
    PubMed    
    
    
    April 2021
92. WATSON MJ, Berger PL, Banerjee K, Frank SB, et al
    Aberrant CREB1 activation in prostate cancer disrupts normal prostate luminal cell differentiation.
    Oncogene. 2021 Apr 12. pii: 10.1038/s41388-021-01772.
    PubMed     Abstract available
    
    
    
93. PUHR M, Eigentler A, Handle F, Hackl H, et al
    Targeting the glucocorticoid receptor signature gene Mono Amine Oxidase-A enhances the efficacy of chemo- and anti-androgen therapy in advanced prostate cancer.
    Oncogene. 2021 Apr 1. pii: 10.1038/s41388-021-01754.
    PubMed     Abstract available
    
    
    
94. PURAYIL HT, Zhang Y, Black JB, Gharaibeh R, et al
    Nuclear betaArrestin1 regulates androgen receptor function in castration resistant prostate cancer.
    Oncogene. 2021;40:2610-2620.
    PubMed     Abstract available
    
    
    
95. ZHOU J, Wang Y, Wu D, Wang S, et al
    Orphan nuclear receptors as regulators of intratumoral androgen biosynthesis in castration-resistant prostate cancer.
    Oncogene. 2021;40:2625-2634.
    PubMed     Abstract available
    
    
    February 2021
96. LIU PI, Chang AC, Lai JL, Lin TH, et al
    Melatonin interrupts osteoclast functioning and suppresses tumor-secreted RANKL expression: implications for bone metastases.
    Oncogene. 2021;40:1503-1515.
    PubMed     Abstract available
    
    
    January 2021
97. KWON OJ, Zhang L, Jia D, Xin L, et al
    Sox2 is necessary for androgen ablation-induced neuroendocrine differentiation from Pten null Sca-1(+) prostate luminal cells.
    Oncogene. 2021;40:203-214.
    PubMed     Abstract available
    
    

Thank you for your interest in scientific medicine.

AMEDEO Prostate Cancer is free of charge.